EP0757697A4 - Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale - Google Patents

Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale

Info

Publication number
EP0757697A4
EP0757697A4 EP95916347A EP95916347A EP0757697A4 EP 0757697 A4 EP0757697 A4 EP 0757697A4 EP 95916347 A EP95916347 A EP 95916347A EP 95916347 A EP95916347 A EP 95916347A EP 0757697 A4 EP0757697 A4 EP 0757697A4
Authority
EP
European Patent Office
Prior art keywords
agents
treatment
viral infection
adhesion molecule
intercellular adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95916347A
Other languages
German (de)
English (en)
Other versions
EP0757697A1 (fr
Inventor
Craig D Wegner
Ernest L Raymond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Publication of EP0757697A1 publication Critical patent/EP0757697A1/fr
Publication of EP0757697A4 publication Critical patent/EP0757697A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95916347A 1994-04-12 1995-04-12 Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale Withdrawn EP0757697A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22599794A 1994-04-12 1994-04-12
PCT/US1995/004519 WO1995027736A1 (fr) 1994-04-12 1995-04-12 Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale
US225997 1999-01-05

Publications (2)

Publication Number Publication Date
EP0757697A1 EP0757697A1 (fr) 1997-02-12
EP0757697A4 true EP0757697A4 (fr) 2000-05-17

Family

ID=22847133

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95916347A Withdrawn EP0757697A4 (fr) 1994-04-12 1995-04-12 Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale

Country Status (4)

Country Link
EP (1) EP0757697A4 (fr)
JP (1) JPH09512252A (fr)
CA (1) CA2187360A1 (fr)
WO (1) WO1995027736A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
AU2004232487A1 (en) * 2003-04-23 2004-11-04 Hansa Medical Ab Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
US20170360815A1 (en) * 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289949A2 (fr) * 1987-05-04 1988-11-09 Dana Farber Cancer Institute Molécules d'adhésion intercellulaire et leurs ligands de liaison
EP0314863A2 (fr) * 1987-11-02 1989-05-10 Baylor College Of Medicine Utilisation du ICAM-1 ou de ses derivés fonctionels pour le traitement des inflammations non spécifiques
EP0391088A2 (fr) * 1989-03-16 1990-10-10 Center For Blood Research Laboratories, Inc. Utilisation de dérivés fonctionnels de la molécule d'adhésion intercellulaire ICAM-1 dans une thérapie anti-virale
WO1993006842A1 (fr) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Utilisation de molecules d'adhesion intercellulaire et de leurs ligands de liaison dans le traitement de l'asthme
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289949A2 (fr) * 1987-05-04 1988-11-09 Dana Farber Cancer Institute Molécules d'adhésion intercellulaire et leurs ligands de liaison
EP0314863A2 (fr) * 1987-11-02 1989-05-10 Baylor College Of Medicine Utilisation du ICAM-1 ou de ses derivés fonctionels pour le traitement des inflammations non spécifiques
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
EP0391088A2 (fr) * 1989-03-16 1990-10-10 Center For Blood Research Laboratories, Inc. Utilisation de dérivés fonctionnels de la molécule d'adhésion intercellulaire ICAM-1 dans une thérapie anti-virale
WO1993006842A1 (fr) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Utilisation de molecules d'adhesion intercellulaire et de leurs ligands de liaison dans le traitement de l'asthme

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KAPELANSKI D P ET AL: "Lung reperfusion injury is reduced by inhibiting a CD18-dependent mechanism.", JOURNAL OF HEART AND LUNG TRANSPLANTATION, (1993 MAR-APR) 12 (2) 294-306;DISCUSSION 306-7., XP000881402 *
ROTHLEIN R ET AL: "TREATMENT OF INFLAMMATION WITH ANTI-ICAM-1", RESEARCH IN IMMUNOLOGY,FR,PARIS, vol. 144, no. 9, 1 January 1993 (1993-01-01), pages 735 - 739,754-76, XP000575989 *
See also references of WO9527736A1 *
WEGNER C D ET AL: "Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma.", SCIENCE, (1990 JAN 26) 247 (4941) 456-9., XP000872999 *
WEGNER, CRAIG D: "Adhesion molecules in allergy", PROG. ALLERGY CLIN. IMMUNOL., PROC. INT. CONGR. ALLERGOL. CLIN. IMMUNOL., 15TH (1995), MEETING DATE 1994, 13-18. EDITOR(S): JOHANSSON, STIG G. O. PUBLISHER: HOGREFE & HUBER, SEATTLE, WASH., XP000881448 *

Also Published As

Publication number Publication date
JPH09512252A (ja) 1997-12-09
CA2187360A1 (fr) 1995-10-19
WO1995027736A1 (fr) 1995-10-19
EP0757697A1 (fr) 1997-02-12

Similar Documents

Publication Publication Date Title
GB9415996D0 (en) Therapeutic agents
GB9415997D0 (en) Therapeutic agents
GB9417310D0 (en) Therapeutic agents
GB9416189D0 (en) Therapeutic agents
GB9416162D0 (en) Therapeutic agents
GB9402641D0 (en) Therapeutic agents
GB9423460D0 (en) Therapeutic agents
EP0757697A4 (fr) Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale
GB9411955D0 (en) Therapeutic agents
GB9409264D0 (en) Therapeutic agents
PL316444A1 (en) Novel agent against viral diseases of respiratory tracts
IL111460A0 (en) Composition for the treatment of viral infections
GB9422923D0 (en) Treatment of viral infections
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease
GB9415405D0 (en) Adherent therapeutic agents
GB9700699D0 (en) Improvements in or relating to diagnostic/therapeutic agents
GB9711845D0 (en) Improvements in or relating to diagnostic/therapeutic agents
GB9711846D0 (en) Improvements in or relating to diagnostic/therapeutic agents
GB9711844D0 (en) Improvements in or relating to diagnostic/therapeutic agents
GB9711842D0 (en) Improvements in or relating to diagnostic/therapeutic agents
GB9711839D0 (en) Improvements in or relating to diagnostic/therapeutic agents
GB9711837D0 (en) Improvements in or relating to diagnostic / therapeutic agents
GB9702195D0 (en) Improvements in or relating to diagnostic/therapeutic agents
GB9407236D0 (en) Therapeutic agents
GB9415556D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000329

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000825

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011108